Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy

Rogowski, Paul; Trapp, Christian; von Bestenbostel, Rieke; Eze, Chukwuka; Ganswindt, Ute; Li, Minglun; Unterrainer, Marcus; Zacherl, Mathias J.; Ilhan, Harun; Beyer, Leonie; Kretschmer, Alexander; Bartenstein, Peter; Stief, Christian; Belka, Claus und Schmidt-Hegemann, Nina-Sophie (2021): Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. In: European journal of nuclear medicine and molecular imaging

Abstract

PURPOSE Nodal recurrent prostate cancer (PCa) represents a common state of disease, amenable to local therapy. PSMA-PET/CT detects PCa recurrence at low PSA levels. The aim of this study was to evaluate the outcome of PSMA-PET/CT-based salvage radiotherapy (sRT) for lymph node (LN) recurrence. METHODS A total of 100 consecutive patients treated with PSMA-PET/CT-based salvage elective nodal radiotherapy (sENRT) for LN recurrence were retrospectively examined. Patients underwent PSMA-PET/CT scan due to biochemical persistence (bcP, 76%) or biochemical recurrence (bcR, 24%) after radical prostatectomy (RP). Biochemical recurrence-free survival (BRFS) defined as PSA < post-RT nadir + 0.2~ng/ml and distant metastasis-free survival (DMFS) were calculated using the Kaplan-Meier method and uni- and multivariate analysis was performed. RESULTS Median follow-up was 37~months. Median PSA at PSMA-PET/CT was 1.7~ng/ml (range 0.1-40.1) in patients with bcP and 1.4~ng/ml (range 0.3-5.1) in patients with bcR. PSMA-PET/CT detected 1, 2, and 3 or more LN metastases in 35%, 23%, and 42%, respectively. Eighty-three percent had only pelvic, 2% had only paraaortic, and 15% had pelvic and paraaortic LN metastases. Cumulatively, a total dose converted to EQD21.5~Gy of 66~Gy (60-70~Gy) was delivered to the prostatic fossa, 70~Gy (66-72~Gy) to the local recurrence, if present, 65.1~Gy (56-66~Gy) to PET-positive lymph nodes, and 47.5~Gy (42.4-50.9~Gy) to the lymphatic pathways. Concomitant androgen deprivation therapy (ADT) was administered in 83% of patients. One-, 2-, and 3-year BRFS was 80.7%, 71.6%, and 65.8%, respectively. One-, 2-, and 3-year DMFS was 91.6%, 79.1%, and 66.4%, respectively. In multivariate analysis, concomitant ADT, longer ADT duration (≥ 12 vs. < 12~months) and LN localization (pelvic vs. paraaortic) were associated with improved BRFS and concomitant ADT and lower PSA value before sRT (< 1 vs. > 1~ng/ml) with improved DMFS, respectively. No such association was seen for the number of affected lymph nodes. CONCLUSIONS Overall, the present analysis shows that the so far, unmatched sensitivity and specificity of PSMA-PET/CT translates in comparably high BRFS and DMFS after PSMA-PET/CT-based sENRT for patients with PCa LN recurrence. Concomitant ADT, duration of ADT, PSA value before sRT, and localization of LN metastases were significant factors for improved outcome.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch